Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)
Phase 3positiveFenebrutinibPositive
AI Analysis
Summary
Genentech announced that fenebrutinib met its primary endpoint in the FENhance 1 Phase III trial for relapsing multiple sclerosis, positioning it as a potential first BTK inhibitor for MS treatment. The positive result represents a significant milestone for this therapeutic candidate in neurology.
Clinical Trial Data
Phase
Phase III
Primary Endpoint
Met
Outcome Details
FENhance 1 pivotal Phase III study met primary endpoint in RMS
Importance:8/10
Sentiment:
0.85
BTK inhibitormultiple sclerosispivotal trialfirst-in-class potentialPhase III
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on March 1, 2026 8:03 PM